Skip to Main Content

Author Details

Marzia Del Re
University of Pisa
2010
148
29
PMIDPaper TitleJournal TitlePublished Year
37696681Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics.Inflamm Bowel Dis2024
38008032Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.Eur J Cancer2024
36822009nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.Cancer Treat Rev2023
37863404Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data.Crit Rev Oncol Hematol2023
37487787Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.Clin Lung Cancer2023
37656059Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.Clin Cancer Res2023
37006303Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.Front Immunol2023
37473500Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC.Lung Cancer2023
36921782Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project.Crit Rev Oncol Hematol2023
36880426Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.Cancer Med2023
36609197TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.Tumori2023
36831647CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients.Cancers (Basel)2023
36736684Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer.Clin Chim Acta2023
31002743Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence.J Med Virol2022
35741115Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool.Diagnostics (Basel)2022
35739016Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.Clin Lung Cancer2022
35476549ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.JCO Precis Oncol2022
35372076Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.Front Oncol2022
35427766EGFR signaling pathway as therapeutic target in human cancers.Semin Cancer Biol2022
35626040Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.Cancers (Basel)2022
35565234The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma.Cancers (Basel)2022
36356286Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.JCO Precis Oncol2022
36283134Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.Breast2022
35974365The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.J Transl Med2022
35131649Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.ESMO Open2022
35151155Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.Cancer Treat Rev2022
35006002Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management.Pharmacogenomics2022
35063635The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences.Crit Rev Oncol Hematol2022
34896250The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.Crit Rev Oncol Hematol2022
34348634Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.Anticancer Agents Med Chem2022
33070443Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA.Mol Oncol2021
33854168Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.Commun Biol2021
33684510Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.Pharmacol Res2021
33544478Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors.Clin Chem Lab Med2021
33540286Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.ESMO Open2021
33673305Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy.Cancers (Basel)2021
33500577Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.Prostate Cancer Prostatic Dis2021
34497081Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol.BMJ Open2021
34434533Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.J Extracell Vesicles2021
34509802Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.ESMO Open2021
34680277A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study.Cancers (Basel)2021
33940185Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives.Pharmacol Res2021
34070018Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study.Cancers (Basel)2021
34178662Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation.Front Oncol2021
34236916Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.J Clin Oncol2021
34145536Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.Drug Saf2021
34091263The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies.ESMO Open2021
34359638Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer.Cancers (Basel)2021
34371157The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies.Crit Rev Oncol Hematol2021
34051303Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer.Crit Rev Oncol Hematol2021
  • 1 - 50 of 148

Recommended Authors

Xue Wu
Nanjing Geneseeq Technology Inc.
Career Start Year 2016
Number of shared co-authors 2
Philip E Lammers
Baptist Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 2
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 1
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 1
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 1
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 0
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 0
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 6
Sadakatsu Ikeda
Tokyo Medical and Dental University Hospital
Career Start Year 2006
Number of shared co-authors 0
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 1
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 4
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 2
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 4
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 3
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 0
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 1
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 8
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 3
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 1
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 1
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 4
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 5
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 2
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Iacopo Petrini
University of Pisa
Co-authored papers 25
Guido Jenster
Erasmus University Medical Center
Co-authored papers 5
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 2
Daniel G Tenen
Harvard Stem Cell Institute, Harvard Medical School
Co-authored papers 2
Giuseppe Curigliano
University of Milan
Co-authored papers 2
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 2
Simon Tiberi
University of Bologna
Co-authored papers 1
Arnulf Stenzl
Eberhard Karls University of Tubingen
Co-authored papers 1
Irene Casanova-Salas
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 1
Marla Weetall
Co-authored papers 1
Edwin M Posadas
Cedars-Sinai Medical Center
Co-authored papers 1
Arun A Azad
Peter MacCallum Cancer Centre
Co-authored papers 1
Raphael Bueno
Co-authored papers 1
Adam G Sowalsky
National Cancer Institute
Co-authored papers 1
David T Miyamoto
Massachusetts General Hospital
Co-authored papers 1
Alexander W Wyatt
University of British Columbia
Co-authored papers 1
Eleni Efstathiou
Houston Methodist Cancer Center
Co-authored papers 1
Alejandro Athie
Vall d'Hebron Institute of Oncology (VHIO)
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Matthias Schwab
and of Biochemistry and Pharmacy, University of Tuebingen
Co-authored papers 1
Guilherme Suarez-Kurtz
Instituto Nacional de Cancer
Co-authored papers 1
Adrián Llerena
Co-authored papers 1
Alexander Drilon
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Mahmoud A Bassal
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 1
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 1
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 1
Robert S Welner
University of Alabama at Birmingham
Co-authored papers 1
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 1
Release 1.2